

SANOFI'S INDIVIDUAL COMMITMENTS IN *act4nature*

Preserving biodiversity and ecosystems and ensuring equitable and sustainable use of natural resources is a key objective on the global scale.

In 2020 the Global Forum of the International Union for Conservation of Nature and the 15th Conference of Parties (COP15) of the Conservation of Biological Diversity will take place in Beijing. In preparation for these international meetings, Sanofi has decided to support the **act4nature** initiative created by EpE, a French association of companies called Entreprises pour l'Environnement, of which it is a member.

This initiative includes 65 large, small and medium-sized companies and scientific, non-governmental and public organisations. The goal of **act4nature** is to mobilise companies to protect, develop and restore biodiversity (www.act4nature.com).

Sanofi has fully incorporated this goal into its sustainable development policy, in particular into its environmental strategy, Planet Mobilisation 2015 -2025. The strategy's aim is to limit the impacts, both direct and indirect, of Sanofi's activities. Five major environmental issues have been identified: greenhouse gas emissions and the fight against climate disruption, water, waste, pharmaceuticals in the environment, and biodiversity.

This strategy covers the entire range of Sanofi's activities all over the world.

Sanofi is aware of the economic, social and societal impact of biodiversity both on the international scale and on the regional level, particularly on populations and their way of life. Sanofi is aware, too, of the ecosystem services that nature renders, and the potential that natural resources, primarily plant and animal resources, represent in terms of medical innovations. As a major actor in the health industries whose focus is on improving patients' health and well-being, Sanofi recognises the need to protect and conserve natural resources and preserve the ecosystems that make up biodiversity.

In its environmental strategy, Sanofi has incorporated management of the risks facing biodiversity -- risks that are either directly related to its sites or have an indirect connection with its value chain.

Our company applies the international agreements that define the principles of preservation of biodiversity, namely the United Nations' Convention on Biological Diversity, Global Compact and Sustainable Development Goals.

In conjunction with its environmental strategy, Planet Mobilisation 2015-2025, Sanofi has undertaken to:

- Comply scrupulously with the 2010 Nagoya Protocol on access to genetic resources and fair and equitable sharing of benefits arising from the use thereof;
- Preserve biodiversity and set up biodiversity management plans in and around all those of its facilities that are identified as sensitive sites by 2020.
- Promote biodiversity among its 100,000 employees through a global awareness program by 2025;
- Continue its policy of environmentally responsible procurement, particularly with respect to biodiversity.

Follow-up of commitments

Coordination of the environmental strategy Planet Mobilisation:

Coordinated by the Director of Industrial Affairs, a steering committee has been formed to define the strategic directions of the Planet Mobilisation program and monitor the progress thereof. Sitting on this committee is a panel representative of Sanofi's organisation and activities (R&D, industrial activities, procurement, transportation, communication, business owners from countries or geographic areas, HSE, etc.).

This committee meets twice a year.

Implementing the Nagoya Protocol:

A dedicated project team began coordinating the implementation of the Nagoya Protocol in 2015. The team monitored implementation of the protocol worldwide in Sanofi entities and analysed the implications it had for R&D, manufacturing and packaging activities, with special attention focused on biological materials.

Today the policy and appropriate processes have been created, and a group of in-house experts reporting to the Bioethical Committee monitors the implementation of the Nagoya protocol.

This committee meets once a year.

Ecotoxicological evaluation of the portfolio

Action was initiated in R&D to assess the impact on the environment of 100% of Sanofi's high-priority products by 2025.

To date, 100% of new products have been analysed and 50 products already on the market have been evaluated on a voluntary basis.

Study of sites' biodiversity sensitivity

In 2014 Sanofi established a mapping of its facilities' vulnerability in terms of biodiversity (fauna, flora, humid areas, protected areas, etc.), following which, the objective of setting up action plans in 100% of the sensitive sites by 2020 was instituted.

To date a pilot study is in progress on one site, prior to being implemented on the other sensitive sites.

Raising employee awareness on biodiversity

Since 2017, events have been organised at Sanofi facilities to bring employees together to focus on a common goal, the preservation of the environment. Beyond raising staff's awareness on the issues at stake and getting them to adapt their behaviours and practices accordingly, these events also offer the opportunity to share all the actions and good practices implemented on all the sites. Biodiversity is at the heart of these events.

In 2018, for World Environment Day, Sanofi mobilised 127 sites in 58 countries.

The "Plan Bee" program launched in 2014 has been rolled out at sites that volunteer for it. To date, beehives have been installed at 22 sites worldwide.

Responsible procurement

This action serves to evaluate and select suppliers, identified as high-priority, according to Corporate Social Responsibility criteria including the Planet Mobilisation strategy.

In 2017, 197 suppliers were evaluated.